Alnylam Pharmaceuticals (ALNY) PT Raised to $86 at Jefferies

August 5, 2016 9:30 AM EDT
Get Alerts ALNY Hot Sheet
Price: $38.22 --0%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 10 | Down: 16 | New: 54
Trade ALNY Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Gena Wang reiterated a Buy rating and raised her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) ti $86.00 (from $80.00) following Q2 update which highlighted progress in clinical programs.

Wang commented, "Following recent data updates (TTR programs, ‘CC5 and fitusiran), we continue to expect rich catalysts in 2H16 including ‘PCSsc (partnered with MDCO) Ph2 data, fitusiran additional Ph1 data, and initial clinical data from multiple programs (‘AAT and ‘GO1). We increase our PT to $86 to reflect increased prob of success for fitusiran program."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $71.03 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Gena Wang

Add Your Comment